PoreWise One finding · Human trial · 2011
Study title
Treatment of localized psoriasis with a topical formulation of zinc pyrithione
- Kind of evidence
- Human trial 2011 · 60 people · patients with localised psoriasis (30/30) · PMID 22367374
- Measured outcome
- Skin effect
- Year
- 2011
- Who was studied
- 60 patients with localised psoriasis (30/30)
- Sample size
- 60
- Measured outcome
- In a randomized, double-blind trial of 60 people with localised psoriasis, a 0.25% zinc pyrithione cream reduced mean PASI from 3.4 to 0.9 over 3 months (p < 0.01) and was significantly better than the emollient base, which changed from 4.3 to 3.9 (p > 0.05).
- Certainty
- Low
- Who was measured
- People with localised psoriasis affecting less than 10% of body surface area, applying the cream twice daily for 3 months.
- Study limits
- Limited to localised, mild psoriasis; an over-the-counter active ingredient.
Where it comes from
- Treatment of localized psoriasis with a topical formulation of zinc pyrithione
Published by Acta Dermatovenerologica Alpina, Pannonica et Adriatica (Sadeghian G, et al.) · Last checked 2026-11-10
Skin concerns studied
Other findings on the same ingredient or concern
- Skin effectSuperiority of a vitamin B(12)-containing emollient compared to a standard emollient in the maintenance treatment of mild-to-moderate plaque psoriasis
In 24 people with mild-to-moderate plaque psoriasis, a vitamin B12-containing ointment reduced PASI by 87.6% from baseline at week 12 versus 23.1% with a standard glycerol-petrolatum emollient on the opposite side (p < 0.001).
Human trial · 2017 · 24 people · patients with plaque psoriasis · Adults with plaque psoriasis in the maintenance phase, applying the ointment twice daily for 12 weeks in a randomised, single-blind, left-right paired design. · Single centre, 24 participants, single-blind, localised left-right design in the maintenance phase; the mainstream high-quality evidence for psoriasis still comes from prescription drugs and biologics.